Get the Stockscreener App
26.80
0.09%
0.025
Pharvaris Nv stock is traded at $26.80, with a volume of 81,978.
It is up +0.09% in the last 24 hours and up +0.98% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$26.77
Open:
$26.88
24h Volume:
81,978
Relative Volume:
0.32
Market Cap:
$1.74B
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-9.4914
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
-3.00%
1M Performance:
+0.98%
6M Performance:
+21.93%
1Y Performance:
+73.46%
1-Day Range:
$26.61
$27.43
1-Week Range:
$26.11
$28.61
52-Week Range:
$11.51
$29.80
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
26.80 | 1.74B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Portfolio Recap: Does Pharvaris NV stock have upside surprise potentialQuarterly Portfolio Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Movement Recap: How correlated is Pharvaris NV to the S P500July 2025 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Pharvaris N.V. (PHVS) Stock Analysis: Exploring a Promising 65.84% Potential Upside in Biotech - DirectorsTalk Interviews
Responsive Playbooks and the PHVS Inflection - Stock Traders Daily
PHVS: Oral HAE therapy shows strong phase III results, with NDA filing and key data expected this year - TradingView
Should You Buy Pharvaris NV (PHVS) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
PHVS Stock Price and Chart — NASDAQ:PHVS - TradingView
Pharvaris N.V. (PHVS) Stock Analysis: A 65% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Advances With New Phase 3 And Phase 2 Data - Sahm
Bain Capital Life Sciences shows 4.3% Pharvaris (PHVS) ownership in Schedule 13G/A - Stock Titan
Understanding the Setup: (PHVS) and Scalable Risk - Stock Traders Daily
Aug Shorts: What is the Moat Score of Pharvaris N.V.2025 Buyback Activity & Smart Swing Trading Techniques - mfd.ru
Pharvaris N.V. (PHVS) Stock Analysis: Potential Upside Of 75% In The Biotech Sector - DirectorsTalk Interviews
Does Pharvaris N.V. stock have upside surprise potentialIPO Watch & Daily Profit Maximizing Trade Tips - mfd.ru
Will Pharvaris N.V. stock gain from lower inflationEarnings Summary Report & Accurate Trade Setup Notifications - mfd.ru
Will Pharvaris N.V. stock recover faster than peersQuarterly Portfolio Review & Comprehensive Market Scan Insights - mfd.ru
Aug Swings: How sensitive is Pharvaris NV to inflationQuarterly Investment Review & Daily Profit Maximizing Tips - baoquankhu1.vn
Oral drug for hereditary angioedema attacks shows Phase 3 data at AAAAI 2026 - Stock Titan
Aug Outlook: Is Pharvaris NV stock a value trapJuly 2025 Big Picture & High Return Trade Guides - baoquankhu1.vn
Aug Gainers: Can Pharvaris NV stock outperform in a bear marketJuly 2025 Sector Moves & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Pharvaris Shares Surge After Strong Phase 3 Results for Oral HAE Treatment - MSN
The Technical Signals Behind (PHVS) That Institutions Follow - Stock Traders Daily
Pharvaris Rings the Opening Bell - Nasdaq
Pharvaris N.V. (PHVS) Stock Analysis: A Biotechnology Gem With 69% Upside Potential - DirectorsTalk Interviews
What’s the fair value of Pharvaris N.V. stockPortfolio Return Summary & Expert Verified Movement Alerts - mfd.ru
Meme Stocks: Is NextNav Inc Equity Warrant exposed to currency risksPortfolio Growth Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Analysts Set Pharvaris N.V. (NASDAQ:PHVS) Target Price at $40.56 - Defense World
Precision Trading with Pharvaris N.v. (PHVS) Risk Zones - Stock Traders Daily
Pharvaris N.V. (PHVS) Stock Analysis: Navigating A 65% Upside In Biotech Innovations - DirectorsTalk Interviews
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Surprises Report: Can Pharvaris NV stock outperform in a bear marketPrice Action & Expert-Curated Trade Recommendations - baoquankhu1.vn
Layoff Watch: Is Box Inc. a speculative investmentWeekly Market Outlook & Short-Term High Return Ideas - baoquankhu1.vn
Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside Gap - Yahoo Finance
Technical Reactions to PHVS Trends in Macro Strategies - Stock Traders Daily
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts - The Globe and Mail
Pharvaris N.V. (PHVS) Stock Analysis: A Promising 83% Upside Potential Amid Biotech Advancements - DirectorsTalk Interviews
Why Pharvaris N.V. stock attracts high net worth investorsMarket Rally & Reliable Price Breakout Signals - Улправда
Why Pharvaris N.V. stock remains a top recommendationOil Prices & Real-Time Market Sentiment Reports - ulpravda.ru
Will Pharvaris N.V. (9EN) stock split increase liquidity2025 Year in Review & Capital Efficient Trade Techniques - Улправда
Street Watch: Why Pharvaris N.V. stock remains a top recommendationDay Trade & Daily Entry Point Trade Alerts - Улправда
How Pharvaris N.V. (9EN) stock reacts to fiscal policiesJuly 2025 PreEarnings & Low Volatility Stock Suggestions - Улправда
How Pharvaris N.V. stock responds to policy changes2025 Market Outlook & Real-Time Volume Trigger Notifications - Улправда
Pharvaris (NASDAQ:PHVS) Shares Up 9.1%Still a Buy? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Down 5.7%What's Next? - MarketBeat
What analysts say about Pharvaris NV stockInstitutional Buying Trends & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
LongTerm Outlook Is Uravi Defence and Technology Limited a BuyandHold StockEarnings Volatility Patterns & Low Cost Stock Ideas - earlytimes.in
CEO Moves: Is Pharvaris NV stock trading near support levelsMarket Performance Report & High Conviction Buy Zone Alerts - moha.gov.vn
Pharvaris (NASDAQ:PHVS) Raised to “Hold” at Wall Street Zen - Defense World
Trading the Move, Not the Narrative: (PHVS) Edition - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Trading 3.8% Higher – What’s Next? - Defense World
Pharvaris N.V. (PHVS) Stock Analysis: Assessing a 66.61% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):